22.95
-1.92%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Fresenius Medical Care
Its shares trade under the ticker FMS. It has been listed since 19 September 1996. In the fiscal year to 31 December 2025, it reported revenue of $22.65bn and net income of $1.13bn. At that date it held total assets of $35.78bn and shareholders' equity of $16.48bn.
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 19 Sept 1996
- Employees
- 109,698
- Website
- freseniusmedicalcare.com ↗
- Head office
- ELSE-KROENER STRASSE 1, BAD HOMBURG, 2M, 61352
- Classification
- Services-Misc Health & Allied Services, NEC
- Filer status
- Large accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company operates a large network of outpatient dialysis clinics globally.
- It develops and manufactures essential healthcare products like hemodialysis machines.
- Revenue is generated through both care delivery and care enablement segments.
Weaknesses
- The source text contains incomplete sentences regarding patient supplies.
- Reliance on specific renal pharmaceuticals creates product concentration risks.
- Operational complexity arises from managing diverse clinical monitoring services.
Opportunities
- Expanding in-licensing agreements for new renal pharmaceuticals can drive growth.
- Increasing demand for home-based dialysis services offers market expansion.
- Developing acute cardiopulmonary products addresses broader medical needs.
Threats
- Regulatory changes in the US and Germany impact dialysis reimbursement.
- Competition in the market for dialysis machines and supplies is intense.
- Supply chain disruptions could affect the delivery of critical medical supplies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.